| Name | Title | Contact Details |
|---|
Lumo Bodytech has developed a technology platform that leverages smart sensors and software to optimize performance and address human biomechanics through the real-time tracking of body movement. Lumo’s products empower you to be the best version of yourself. Current Lumo Bodytech products include the Lumo Lift and Lumo Back posture coaches and activity trackers, as well as the Lumo Run smart running shorts.
Blooming Behavior Services is a company that provides Applied Behavior Analysis (ABA) therapy to children with Autism and related disorders. They offer tailored treatment plans based on research-based strategies with intense personal attention.
Swisher Memorial Hospital District's mission is to improve our quality of care and increase our services to meet the increasing healthcare demands for Swisher County and surrounding counties.
Northern Maine General is a non-profit social service organization located in Eagle Lake, Maine. The Maine State Legislature created NMG in 1907. At that time, it was both a hospital and a home for the aged under the care of the Little Franciscan Sisters
Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company`s focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV. Bionor Pharma`s most advanced product candidate is Vacc-4x, which is also the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Pharma`s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the HDAC inhibitor romidepsin in the REDUC study. In May 2015, Bionor Pharma announced promising results from an interim analysis of Part B of the REDUC study. In the study, Vacc-4x and romidepsin are explored as a possible treatment regimen to reduce the persistent latent viral reservoir in HIV infected patients on anti-retroviral treatment. Results are expected in the second half of 2015. Bionor Pharma is headquartered in Oslo, Norway, with offices in Copenhagen and New York.